Explore published research on workplace, including study methods and limitations.
Review of European workplace drug testing finding it far less standardized than US programs, with cannabis as the most frequently detected substance and significant gaps in quality control.
Study found cannabis users had lower alertness and slower cognition in work-related testing but did not report more workplace errors, with effects showing "hangover" and fatigue-related patterns.
A four-year drug testing program in the Finnish military tested over 2,000 samples and found only one case of illicit drug use (cannabis and amphetamine).
Lowering the cannabis urine test cutoff from 15 to 5 ng/mL caught 25.2% more positive results in French military screening without creating false positives.
Only 0.7% of Italian workers in safety-sensitive jobs tested positive for drugs, likely because the law requires them to be notified the day before testing.
National survey data showed drug-free workplace policies and EAPs were each associated with 15% lower odds of marijuana use and prescription drug misuse in young workers.
Review of THC detection methods across blood, urine, saliva, and hair highlights growing challenges for drug testing programs as legal medical cannabis products like Sativex produce positive results.
Analysis of employed Americans found medical and recreational cannabis users were more similar than different after controlling for health factors, except medical users were more concentrated in construction and mining.
Washington State data shows marijuana use declined among younger teens after legalization but increased among working 12th graders relative to non-working peers, especially those working more hours.
NIOSH commentary identified that cannabis legalization outpaced workplace research — drug testing can't measure current impairment, and safety policies lack evidence.
Officers at outdoor concerts had measurable airborne THC exposure and 34% had a THC metabolite in urine, but all levels were far below impairment or drug-screening thresholds.
Survey of 1,651 Canadian workers found 25% of cannabis users had used at or before work. Workplace users were more likely to use daily, use high-THC, and use for medical reasons.
Oral fluid drug tests matched urine results well across drug classes. Cannabis was detectable with a shorter detection window — potentially better for measuring recent use.
25 years of Swedish workplace drug testing showed positive results quadrupling from 1.3% to 5.6%, with cannabis becoming the most detected substance after 2007.
Employers face conflicting laws and unreliable drug tests — a practical framework for cannabis workplace policies addresses safety, legal protections, and impairment measurement.
Researchers created a practical clinical framework for assessing cannabis-related impairment risk in patients, designed especially for those with safety-sensitive work duties.
Controlled study of 21 people found oral cannabis produced positive urine tests 97.6% of the time versus 59.5% for vaporized cannabis at standard workplace cutoffs.
Longitudinal study of 2,745 Canadian workers found cannabis use at work nearly doubled injury risk, while off-the-job use showed no increased risk.
Review of 31 systematic reviews found medical cannabis commonly causes sedation, dizziness, and euphoria, all of which could reduce workplace safety.
One in four positive workplace drug tests now contain delta-8 THC metabolites — 11% from delta-8 exclusively — creating new challenges for testing programs and employees alike.
National survey of 46,499 workers found a clear dose-response: mild CUD increased work-skipping 1.6x, moderate 2.0x, and severe 2.9x, with 15.9% of full-time workers reporting past-month cannabis use.
ACOEM guideline found no quality evidence supporting cannabis for common work-related pain conditions and recommended against use in safety-sensitive positions.
Among 23,900 Swedish workplace drug tests, 4.6% were positive—with cannabis the most common substance at over 40% of positive results.
A survey of 26,458 US workers found 7.4% used cannabis at or near work, with highest rates in legal states, high-risk jobs, and among medical cardholders.
After legalizing private cannabis use, South Africa faces the challenge of workplace testing—this paper proposes impairment-based THC thresholds over zero-tolerance approaches.
A nationally representative study found 8.9% of US workers in their early 30s used substances at work, with 3.1% using marijuana, highest in food service and safety-sensitive jobs.
Multi-state surveillance identified 30 cases of work-related asthma in cannabis workers, mostly from dust exposure in indoor cultivation, including two fatalities.
Legal CBD products with trace THC caused positive oral fluid drug tests in up to 80% of participants, and even pure CBD products produced some false positives due to analytical conversion during testing.
Multi-state analysis of social equity programs in legal cannabis found wide variation in design and outcomes, with persistent gaps between policy goals and actual representation.
National survey of 25,000 Australian workers found 5% use cannabis weekly, with at-risk users missing nearly 7 extra work days annually — concentrated in construction, hospitality, and trades.
Systematic review of 92 studies found even low THC doses can trigger positive urine tests, and regular users may test positive for weeks — exposing problems with current thresholds.